Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14253834 | 0.79 | PTGS2 (0.80) | PTGS2PTGS1PDE3A | |
| SCHEMBL2760349 | 0.78 | PTGS2 (1.00) | PTGS2PTGS1PDE3A | |
| SCHEMBL4586989 | 0.73 | PTGS2 (0.88) | PTGS2PTGS1PDE3A | |
| SCHEMBL2777180 | 0.72 | PTGS2 (0.60) | PTGS2GPBAR1PTGS1PDE3AMAPT | |
| SCHEMBL5729316 | 0.71 | PTGS2 (0.60) | PTGS2PTGS1PDE3ANPC1MAPT | |
| SCHEMBL11893877 | 0.71 | ALDH1A1 (0.61) | PTGS2GPBAR1PTGS1RAB9ASMN1; SMN2 | |
| SCHEMBL2723582 | 0.71 | GPBAR1 (0.62) | PTGS2GPBAR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7558640 | 0.71 | MEN1 (0.68) | PTGS2GPBAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8574591 | 0.70 | PTGS2 (0.58) | PTGS2PTGS1PDE3ANPC1MAPT | |
| SCHEMBL8251665 | 0.70 | PTGS2 (0.57) | PTGS2GPBAR1PTGS1PDE3ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492773-B1 | 4-(HETEROCYCLYL)-BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | CADILA HEALTHCARE LTD (IN) | 2009-02-04 | — | — | EP | disclosed |
| US-7348342-B2 | Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-20050277678-A1 | Heterocyclic compounds process for their preparation and pharmceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2005-12-15 | — | — | US | disclosed |
| EP-1492773-A2 | 4-(HETEROCYCLYL)-BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | CADILA HEALTHCARE LTD. (IN) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087062-A2 | 4-(HETEROCYCLYL)-BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | CADILA HEALTHCARE LIMITED (IN) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277678-A1 | Heterocyclic compounds process for their preparation and pharmceutical compositions containing them and their use in medicine | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HPGDS, LTC4S | PTGS2 27/4885GPBAR1 1192/4885PTGS1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.